Lenalidomide

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, April 20, 2023

HOUSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced the presentation of two posters related to the company’s novel molecular glue, SP-3164, at the American Association for Cancer Research (AACR) Annual Meeting. Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).

Key Points: 
  • Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).
  • “These two studies presented at the prestigious AACR Annual Meeting are adding to the growing body of SP-3164 preclinical data demonstrating anticancer activity alone and in combination with standard-of-care treatments,” said David Arthur, president and chief executive officer of Salarius.
  • In addition, the data showed SP-3164 induced apoptosis in multiple myeloma cell lines.
  • In animal models, SP-3164 demonstrated superior single-agent activity compared to both lenalidomide (Revlimid®) and pomalidomide (Pomalyst®).

Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • In various multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) tumor models, ICP-490 demonstrates superior tumor killing activities, including overcoming lenalidomide resistance.
  • Cell viability assays reveal robust in vitro efficacies of ICP-490 against various MM and NHL(including DLBCL) cell lines with nanomolar IC50.
  • In contrast to its tumor killing effect, ICP-490 shows no cytotoxicity against normal human cells.

EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Retrieved on: 
Monday, April 17, 2023

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Key Points: 
  • MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
    BOSTON and WILMINGTON, Del.
  • Monjuvi, in combination with lenalidomide, was granted accelerated approval based on the one-year primary analysis of the L-MIND study.
  • The data for the five-year analysis of the L-MIND study have not yet been submitted to, or reviewed by, the FDA.

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Retrieved on: 
Sunday, April 16, 2023

A partial response (PR) was observed in 16.2% of patients (95% CI = 8.9, 26.2; n =13).

Key Points: 
  • A partial response (PR) was observed in 16.2% of patients (95% CI = 8.9, 26.2; n =13).
  • Additional results include:
    Median duration of response was not reached after a median follow up of 44.0 months (95% CI = 29.9, 57.0).
  • Monjuvi, in combination with lenalidomide, was granted accelerated approval based on the one-year primary analysis of the L-MIND study.
  • The data for the five-year analysis of the L-MIND study have not yet been submitted to, or reviewed by, the FDA.

EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

Retrieved on: 
Saturday, April 15, 2023

The topline data are now expected by the end of 2023, earlier than previously anticipated.

Key Points: 
  • The topline data are now expected by the end of 2023, earlier than previously anticipated.
  • Myelofibrosis – which belongs to a group of diseases called myeloproliferative disorders – is a difficult-to-treat form of blood cancer with limited treatment options.
  • Enrollment of the Phase 3 frontMIND study is also complete, with more than 880 patients enrolled in the trial.
  • The topline data from this study are expected in the second half of 2025.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021.
  • Research and development expenses were $4.7 million in the fourth quarter of 2022, compared with $2.7 million in the fourth quarter of 2021.
  • As of December 31, 2022, Salarius had cash, cash equivalents and restricted cash of $12.1 million, compared with $29.2 million as of December 31, 2021.
  • Current cash and cash equivalents are expected to fund the company’s planned operations into the fourth quarter of 2023.

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Retrieved on: 
Thursday, March 23, 2023

Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.

Key Points: 
  • Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.
  • General and administrative: For the quarter ended on December 31, 2022, there was no significant variation in General and administrative expenses.
  • Research and development expenses: For the quarter ended on December 31, 2022, there was no significant variation in Research and development expenses.
  • In addition, during the fourth quarter of 2022, Knight also submitted a branded generic of for regulatory approval in Chile and Colombia.

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023

MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.

Key Points: 
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the fourth quarter  2022 and € 3.0 million for the full year of 2022.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 15, 2023

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
  • ET)
    Five-Year Safety and Efficacy of Tafasitamab in Patients with Relapsed or Refractory DLBCL: Final Results from the Phase 2 L-MIND Study1(Abstract #CT022.
  • ET)
    For registered attendees, the virtual meeting platform and all on-demand sessions will be available through July 19, 2023.
  • More information regarding the AACR Annual Meeting 2023 can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2023/ .